Sugi Predict

Sugi Predict / Compounds / SCHEMBL8224149

SCHEMBL8224149

SCHEMBL8224149

Cc1oc(C(C)(C)C)cc1C(C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ CYP26A1 O43174 4/20 0.37
▸ PKM P14618 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ TSHR P16473 3/20 0.33
▸ USP2 O75604 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ MAPT P10636 2/20 0.32
▸ ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21479468 0.81 LMNA (0.33) LMNA
SCHEMBL13487533 0.78 MEN1 (0.33) L3MBTL1KMT2AMEN1ALOX15
SCHEMBL24805358 0.75 L3MBTL1 (0.42) L3MBTL1KMT2AMEN1CYP26A1PKM
SCHEMBL12848813 0.74 CA1 (0.35) NPC1RAB9ATSHRLMNAGAA
SCHEMBL7355993 0.74 L3MBTL1 (0.41) L3MBTL1KMT2AMEN1CYP26A1PKM
SCHEMBL3106702 0.73 BRD4 (0.38) L3MBTL1KMT2AMEN1NPC1RAB9A
SCHEMBL9909954 0.72 KMT2A (0.52) L3MBTL1KMT2AMEN1CYP26A1PKM
SCHEMBL4298346 0.72 ALOX5 (0.48) KMT2AMEN1CYP26A1LMNAMAPT
SCHEMBL820796 0.70 L3MBTL1 (0.48) L3MBTL1KMT2AMEN1CYP26A1PKM
SCHEMBL21718795 0.68 L3MBTL1 (0.47) L3MBTL1KMT2AMEN1CYP26A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180162862-A1 INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-06-14 — — US disclosed
US-20100144591-A1 BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-06-10 — — US disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — US disclosed
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant SCHERING CORPORATION 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant CNR2, GPR119, GLP1R L3MBTL1 2967/4885KMT2A 193/4885MEN1 991/4885
US-20180162862-A1 INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES SI, UGGT1, ALPI L3MBTL1 846/4885KMT2A 2738/4885MEN1 3913/4885
US-20100144591-A1 BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GK, GCK L3MBTL1 2233/4885KMT2A 3347/4885MEN1 4310/4885
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES MAP4K2, MAP3K1, MAP3K20 L3MBTL1 3324/4885KMT2A 3153/4885MEN1 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.